Biofield Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 9 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 3.53%
(FY 2023)
- Profit 13.99%
(FY 2023)
- Ebitda 9.68%
(FY 2023)
- Net Worth 31.62%
(FY 2023)
- Total Assets -1.78%
(FY 2023)
About Biofield Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Deepshikha and Ashmit Kaushal serve as directors at the Company.
- CIN/LLPIN
U24233CH2015PTC035831
- Company No.
035831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Nov 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Manimajra, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Biofield Pharma Private Limited offer?
Biofield Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Dietary Supplements, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Pharmaceutical Capsules.
Who are the key members and board of directors at Biofield Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepshikha  | Director | 01-Jul-2023 | Current |
| Ashmit Kaushal | Director | 20-Nov-2015 | Current |
Financial Performance of Biofield Pharma.
Biofield Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.53% increase. The company also saw a substantial improvement in profitability, with a 13.99% increase in profit. The company's net worth Soared by an impressive increase of 31.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biofield Pharma?
In 2023, Biofield Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stelon Biotech Private LimitedActive 3 years 10 daysDeepshikha and Ashmit Kaushal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biofield Pharma?
Unlock and access historical data on people associated with Biofield Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biofield Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biofield Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
